Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677911 · ClinicalTrials.gov registry record · Early Phase 1
Immunologic Response to Negative Cognition in Persons With Chronic Pain
A Early Phase 1 study of Chronic Pain, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT00677911: Completed Early Phase 1 study of Chronic Pain, sponsored by Oregon Health and Science University.
NCT00677911 is a Early Phase 1 study of Chronic Pain that has completed, run by Oregon Health and Science University. The registered enrollment target is 47 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00677911, a Early Phase 1 study of Chronic Pain, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page Summary: Chronic pain is stressful, both physically and psychologically. Stressful experiences induce autonomic nervous system arousal, which reliably leads to inflammation and immune suppression. Inflammation then exacerbates existing pain and may be a key factor in both the genesis and maintenance of pain. Stress-induced immune effects are detected two hours (2 hrs) post-stressor, suggesting only a few stressful experiences per day may be sufficient to sustain elevated pain levels1. Cognition has emerged as a potential mediating factor in the relationship between pain and stress. Mentally recreating an emotionally stressful event induces de novo physiological stress1. In other words, thinking about an emotionally charged event down-regulates autonomic stress responses and subsequent immune effects. Therefore, exploring cognition as a mediating factor between stress, pain, and inflammation will inform our understanding of pain pathways, as well as improve treatment for pain. Study Rationale: The acute stress response induces immunosuppression; however, this relationship has been studied in arbitrary models only (shock avoidance, job interview). This study employs the novel approach of examining stress and immune responses to a personally relevant stressor (pain); prior studies used arbitrary models only (shock avoidance, job interview). Pain offers a highly salient and personal context well-suited for investigation of negative cognitive perseveration. Pain is acutely sensitive to exacerbation via inflammation, and thus the relevance of examining immune effects of rumination on future negative expectations ("expecting the worst") is underscored. Goal: To test the biological consequences of negative expectations, achieved via an active 10-minute negative cognitive perseveration on a personally rel
Conditions Studied
Interventions
- BEHAVIORAL In-vivo pain catastrophizing induction
Study Locations (1)
Oregon
- OCTRI; OHSU Mail Code: CHH 13th floor 3303 Bond St. - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-12 |
| Phase | Early Phase 1 |
What the finished NCT00677911 record still lists
NCT00677911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which In-vivo pain catastrophizing induction is the first listed.
NCT00677911 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00677911 about?
NCT00677911 is a clinical study titled "Immunologic Response to Negative Cognition in Persons With Chronic Pain". Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page Summary: Chronic pain is stressful, both physically and psychologically. Stressful experiences induce autonomic nervous system ar...
What is the current status of trial NCT00677911?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 47 participants. The study started on 2007-02. Estimated completion is 2007-12.
What conditions does trial NCT00677911 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT00677911?
The interventions under investigation include: In-vivo pain catastrophizing induction (BEHAVIORAL).
Who is sponsoring clinical trial NCT00677911?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677911 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00677911's enrollment target sits among peer trials
47 205th of 301 higher than 97 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cannabidiol in Opioid Use Disorder and Chronic Pain
RECRUITING · Early Phase 1
-
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
-
Managing Chronic Pain in Veterans With Substance Use Disorders
COMPLETED · Early Phase 1
-
Non-Opioid Pramipexole and Pain
COMPLETED · Early Phase 1
-
Exploratory Evaluation of [11C]-NOP46
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia